Rajeev M. Shah
CIK 1619841 · last filed 2026-07-14
Rajeev M. Shah is a corporate insider who has filed 111 SEC Form 4 insider transactions across 40 companies since 2016. The most recent filing shows the insider bought $1.2M of ARTV on Jul 14, 2026. Across all open-market trades the lifetime net is +$4.54B, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.62B across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.62B
Companies
40
Total Filings
111
Lifetime Open-Market Net
$4.54B
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARTV | Director | 68,320 | $10.47 | $715.3K | $2.92M | 2 | 2026-07-14 |
| ACRV | Director | 9,366 | $1.51 | $14.2K | $211.84M | 3 | 2026-06-22 |
| HOWL | Director | 341,353 | $0.45 | $153.2K | $111.50M | 3 | 2026-06-16 |
| PBLS | Director | 26,285,093 | — | — | $2.12B | 2 | 2026-06-15 |
| Climb Bio, Inc. (ELYM) Delisted | Director | 2,866,375 | $5.11 | $14.65M | $5.28M | 6 | 2026-06-08 |
| COAG | Director | 6,372,170 | $47.11 | $300.19M | $313.97M | 2 | 2026-05-14 |
| ACET | 10%+ Owner | 932,624 | $8.10 | $7.55M | $0 | 1 | 2026-04-29 |
| PRLD | 10%+ Owner | 6,475,882 | $4.68 | $30.31M | $0 | 1 | 2026-04-28 |
| VOR | Director | 3,936,436 | $19.97 | $78.61M | -$82.92M | 4 | 2026-04-10 |
| ABOS | Director | 19,103,785 | $2.28 | $43.56M | $350.00M | 4 | 2026-03-18 |
| SGP | Director | 2,054,678 | $21.43 | $44.03M | $295.20M | 1 | 2026-02-11 |
| FULC | 10%+ Owner | 8,852,079 | $3.73 | $33.06M | -$233.41M | 2 | 2025-12-10 |
| WVE | Director | 28,815 | $5.92 | $170.6K | $20.00M | 3 | 2025-08-13 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Director | 3,365,523 | $221.38 | $745.06M | $400.00M | 2 | 2025-06-30 |
| SPRY | Director | 902,904 | $5.71 | $5.16M | $116.25M | 3 | 2025-06-27 |
| TYRA | Director | 10,127,311 | $30.94 | $313.34M | $8.32M | 1 | 2025-06-16 |
| NKTX | Director | 754,311 | $2.24 | $1.69M | $0 | 2 | 2025-06-09 |
| JANX | Director | 10,031,081 | $14.91 | $149.56M | $326.71M | 2 | 2025-03-07 |
| 89bio, Inc. (ETNB) Delisted | Director | 4,965,769 | $14.84 | $73.69M | $31.91M | 5 | 2024-11-18 |
| Satsuma Pharmaceuticals, Inc. (STSA) Delisted | Director | 0 | $1.10 | $0 | $20.00M | 5 | 2023-06-08 |
| BDTX | Director | 311,926 | $1.75 | $547.4K | $19.00M | 7 | 2023-05-17 |
| MLYS | Director | — | $26.95 | — | $0 | 1 | 2023-02-13 |
| CTKB | Director | 12,459,692 | $4.46 | $55.57M | $69.40M | 2 | 2022-03-11 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | 28,207 | $93.80 | $2.65M | $195.00M | 1 | 2021-07-06 |
| SLDB | Director | 772,019 | $8.00 | $6.18M | $66.75M | 10 | 2021-06-21 |
| KALA | Director | 4,370 | $0.65 | $2.8K | $78.00M | 8 | 2021-06-21 |
| PHAT | 10%+ Owner | 3,115,008 | $11.68 | $36.38M | -$124.25M | 1 | 2021-03-15 |
| Iterum Therapeutics plc (ITRM) Delisted | 10%+ Owner | 776,773 | $0.03 | $23.3K | $0 | 1 | 2021-02-08 |
| DYN | 10%+ Owner | 2,805,045 | $26.08 | $73.16M | $37.62M | 1 | 2020-09-23 |
| TGTX | 10%+ Owner | 12,629,868 | $54.74 | $691.33M | -$12.28M | 1 | 2020-09-11 |
| INBX | 10%+ Owner | 2,129,003 | $79.47 | $169.19M | $0 | 1 | 2020-08-24 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | 10%+ Owner | 4,417,259 | $10.15 | $44.84M | $81.22M | 1 | 2020-07-29 |
| Inozyme Pharma, Inc. (INZY) Delisted | 10%+ Owner | 1,403,653 | $4.00 | $5.61M | $28.80M | 1 | 2020-07-28 |
| Pandion Therapeutics, Inc. (PAND) Delisted | 10%+ Owner | 1,408,912 | $60.05 | $84.61M | $19.50M | 1 | 2020-07-22 |
| RYTM | 10%+ Owner | 5,210,088 | $107.83 | $561.78M | -$25.47M | 2 | 2020-07-02 |
| Eidos Therapeutics, Inc. (EIDX) Delisted | Director | 1,103,847 | — | — | $18.00M | 4 | 2020-05-29 |
| VSTM | 10%+ Owner | 1,441,946 | $6.22 | $8.98M | -$12.01M | 1 | 2020-04-29 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | 0 | — | — | $32.70M | 7 | 2020-04-03 |
| IMRA | 10%+ Owner | 363,587 | $14.46 | $5.26M | $40.00M | 1 | 2020-03-17 |
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 1,441,070 | $27.00 | $38.91M | $7.22M | 4 | 2017-10-16 |
Recent Filings
111 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-14 | ARTV | Buy (P) | +129,924 | $1.16M | EDGAR |
| 2026-06-29 | ARTV | Buy (P) | +197,256 | $1.75M | EDGAR |
| 2026-06-22 | ACRV | Grant (A) | — | $0 | EDGAR |
| 2026-06-16 | HOWL | Sell (S) | −1,795,344 | -$695.0K | EDGAR |
| 2026-06-15 | PBLS | Mixed | +144,666,855 | $2.12B | EDGAR |
| 2026-06-11 | PBLS | Grant (A) | — | $0 | EDGAR |
| 2026-06-08 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2026-05-20 | ACRV | Grant (A) | +46,830 | $0 | EDGAR |
| 2026-05-14 | COAG | Buy (P) | +25,548 | $636.1K | EDGAR |
| 2026-05-06 | COAG | Mixed | +46,071,090 | $313.34M | EDGAR |
Showing 1–10 of 111
Page 1 of 12
Next
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.